ReviewNature reviews. Disease primers2022
Urticaria.
Review in Nature reviews. Disease primers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
190 citing papers in PubMed, 5 syntheses or guidelines pooled it, 324 citations in OpenAlex.
- The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.Allergy · 2026Guideline
- Urticaria as a dermatologic manifestation of Giardia infection: a systematic review of clinical, diagnostic, and therapeutic features.BMC infectious diseases · 2025Pooled it
- Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Clinical drug investigation · 2025Pooled it
- The prevelance of food allergy in patients with chronic idiopathic urticaria: a systematic review and meta-analysis.Archives of dermatological research · 2024Pooled it
- A systematic review of studies that estimated the burden of chronic non-communicable rare diseases using disability-adjusted life years.Orphanet journal of rare diseases · 2024Pooled it
- Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.The British journal of dermatology · 2024Trial
- Chronic Spontaneous Urticaria and Psychiatric Symptoms: The Blood-Brain Barrier Hypothesis.Experimental dermatology · 2026Review
- CH50 as a Clinically Useful Biomarker of Disease Activity and Antihistamine Resistance in Chronic Spontaneous Urticaria: An Observational Ambispective Single-Center Study.International journal of dermatology · 2026Observational
- Chronic Spontaneous Urticaria in Finland - A Nationwide Registry Study on Epidemiology and Treatment Patterns in Secondary Care.Acta dermato-venereologica · 2026Article
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics · 2026Review
- Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.Fortune journal of health sciences · 2026Article
- Article
- Research on chronic urticaria and angioedema: A bibliometric analysis of Web of Science Core Collection.Immunologic research · 2026Review
- Integrated Traditional Chinese and Western Medicine for Chronic Spontaneous Urticaria: Protocol for a Trials Within Cohorts Study.JMIR research protocols · 2026Article
- Clinical and Immunological Associations of Plasma Platelet-Activating Factor in Chronic Spontaneous Urticaria.Biomedicines · 2026Article
- The Burden of Urticaria in the Middle East and North Africa Region From 1990 to 2021: A Systematic Analysis Based on the GBD Study 2021.Health science reports · 2026Article
- Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study.Dermatology and therapy · 2026Article
- RECOVER Guidelines: First Aid. Evidence, Treatment Recommendations, Knowledge Gap Analysis, and Clinical Guidelines for Acute Allergy and Anaphylaxis in Dogs and Cats.Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) · 2026Article
- Dermographometer assessment in children with urticaria.The World Allergy Organization journal · 2026Article
- Article
130 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urticaria is an inflammatory skin disorder that affects up to 20% of the world population at some point during their life. It presents with wheals, angioedema or both due to activation and degranulation of skin mast cells and the release of histamine and other mediators. Most cases of urticaria are acute urticaria, which lasts ≤6 weeks and can be associated with infections or intake of drugs or foods. Chronic urticaria (CU) is either spontaneous or inducible, lasts >6 weeks and persists for >1 year in most patients. CU greatly affects patient quality of life, and is linked to psychiatric comorbidities and high healthcare costs. In contrast to chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) has definite and subtype-specific triggers that induce signs and symptoms. The pathogenesis of CSU consists of several interlinked events involving autoantibodies, complement and coagulation. The diagnosis of urticaria is clinical, but several tests can be performed to exclude differential diagnoses and identify underlying causes in CSU or triggers in CIndU. Current urticaria treatment aims at complete response, with a stepwise approach using second-generation H1 antihistamines, omalizumab and cyclosporine. Novel treatment approaches centre on targeting mediators, signalling pathways and receptors of mast cells and other immune cells. Further research should focus on defining disease endotypes and their biomarkers, identifying new treatment targets and developing improved therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.